Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04529122
Other study ID # MX39897
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date August 27, 2020
Est. completion date December 31, 2026

Study information

Verified date April 2024
Source Hoffmann-La Roche
Contact Reference Study ID # MX39897 https://forpatients.roche.com/
Phone 888-662-6728
Email global-roche-genentech-trials@gene.com
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

WAYFIND-R is a registry that aims to capture high-quality real-world data linking next-generation sequencing, treatments and outcomes from cancer patients diagnosed with a solid tumour. The WAYFIND-R has three main overarching objectives: 1. To provide a platform to support the design and conduct of clinical and epidemiological research; 2. To develop an evidence-generation platform to better understand health outcomes and cancer care processes; and 3. To characterize the treatments and clinical course of solid tumor cancers in patients who have undergone NGS testing.


Recruitment information / eligibility

Status Recruiting
Enrollment 15000
Est. completion date December 31, 2026
Est. primary completion date December 31, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Participant is an adult (according to the age of majority as defined by local regulations) - Participant is currently diagnosed with any type of solid tumour cancer, at any stage of the disease, at the enrollment date (informed consent date) - Participant has undergone NGS testing, no longer than 3 months prior to the enrollment date, irrespective of the availability of test results - Informed consent has been obtained from the participant or legally authorized representative, as per local regulations Exclusion Criteria: -Participant has a prior or current diagnosis of haematological malignancy

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Argentina Cemic; Oncologia Clinica Buenos Aires
Argentina Hospital Italiano Buenos Aires
Argentina Instituto Alexander Fleming Buenos Aires
Austria LKH-UNIV. KLINIKUM GRAZ; Klinische Abteilung für Onkologie Graz
Brazil Hospital Moinhos de Vento Porto Alegre RS
Brazil D'or Instituto de Pesquisa e Educação Sao Paulo SP
Brazil Hospital Alemao Oswaldo Cruz Sao Paulo SP
Brazil Instituto do Cancer do Estado de Sao Paulo - ICESP Sao Paulo SP
Brazil Beneficencia Portuguesa de Sao Paulo São Paulo SP
Canada Alberta Health Services Calgary Alberta
Canada The Ottawa Hospital - General Campus Ottawa Ontario
Chile Centro de Oncología de Precisión Las Condes
Chile Centro de Cancer Pontificie Universidad Catolica de Chile Santiago
Colombia Clinica del Country Bogota
Colombia Fundacion Cardioinfantil Bogota
Colombia Hospital Universitario Mayor MEDERI Bogota
Colombia Fundación CTIC - Centro de Tratamiento e Investigación sobre Cáncer Luis Carlos Sarmiento Angulo Bogota, D.C.
Colombia Organizacion Sanitas Internacional Bogota, D.C.
Colombia Fundacion Clinica Valle del Lili; Unidad de Investigaciones Clinicas Cali
Colombia Clinica ASTORGA Medellin
Colombia Instituto Cancerologia Medellin; Clinica Las Americas Medellin
Egypt International Medical Center; Oncology Department Cairo
Estonia East Tallinn Central Hospital; Clinic of Internal Medicine Tallinn
Estonia North Estonia Medical Centre Foundation; Oncology Center Tallinn
Estonia Tartu Uni Hospital; Surgery Clinic Tartu
France HOPITAL JEAN MINJOZ; Oncologie Besancon
France Chu Brest - Hôpital Morvan Brest
France Centre Francois Baclesse; Recherche Clinique Caen
France Centre Jean Perrin; Division De Recherche Clinique Clermont Ferrand
France Hôpital Franco-Britannique- Fondation Cognacq-Jay; Cancerologie Levallois-Perret
France Centre Oscar Lambret Lille
France Centre Leon Berard; Oncologie Genetique Lyon
France Aphm; Cpcet Marseille
France Institut Curie Paris
France CH de Cornouailles Quimper
France Centre Eugene Marquis Rennes
France CHU Saint Etienne - Hôpital Nord Saint Etienne
France Hôpital Privé de la Loire, Ramsay Saint Etienne St Etienne
France CHI de Toulon - Hôpital Sainte Musse Toulon
France Gustave Roussy Villejuif
Germany HELIOS Klinikum Bad Saarow; Klinik Hämatologie, Onkologie und Palliativmedizin, Sarkomzentrum Bad Saarow
Germany Universitätsklinikum Halle (Saale); Krukenberg- Krebszentrum Halle; onkologisches Zentrum Halle (Saale)
Germany Medizinische Hochschule Hannover; Klinik für Gastroenterologie, Hepatologie und Endokrinologie Hannover
Germany SLK-Kliniken Heilbronn GmbH; Klinik für Innere Medizin III; Schwerpunkt Häma./Onko./Palliativm. Heilbronn
Germany Katharinenhospital Stuttgart; Klinik für Hämatologie, Onkologie und Palliativmedizin Stuttgart
Germany Marien-Hospital Wesel; Klinik für Gastro., Onko. + Häma., Diabetologie und Rheumatologie Wesel
Greece General Hospital "G.Papanikolaou"; Pulmonogy Clinic Asvestochori
Greece Alexandras General Hospital of Athens; Oncology Department Athens
Greece Henri Dunant Hospital; Oncology Dept. Athens
Greece Metropolitan Hospital Fourth Oncology Clinic Faliro
Greece Bioclinic Thessaloniki Thessaloniki
India Manipal Hospital; Department of Oncology Bangalore Karnataka
India HealthCare Global Enterprises Limited; Medical Oncology Banglore Karnataka
India Apollo Hospitals; Medical Oncology Chennai Tamil NADU
India American Oncology Institute Hyderabad Andhra Pradesh
India Indo-American Cancer Hospital & Research Center Hyderabad Telangana
India MOC Cancer Care & Research Centre (Unit of Cellcure Cancer Centre Pvt Ltd) Mumbai Maharashtra
India Tata Memorial Hospital; Dept of Medical Oncology Mumbai Maharashtra
India Max Super Speciality Hospital New Delhi Delhi
India Bhaktivedanta Hospital and research institute Thane Maharashtra
Ireland Adelaide & Meath Hospital, Dublin, Incorporating the National Children's Hospital; Oncology Day Unit Dublin
Ireland St James's Hospital Dublin
Ireland St Vincent'S Uni Hospital; Medical Oncology Dublin
Israel Hadassah University Hospital - Ein Kerem Jerusalem
Israel Sourasky / Ichilov Hospital; Dept. of Oncology Tel Aviv
Lebanon American University of Beirut - Medical Center Beirut
Lebanon Hotel Dieu de France; Oncology Beirut
Lebanon Hammoud Hospital Saida
Mexico ONCARE Viaducto Napoles Ciudad de México Mexico CITY (federal District)
Mexico Clínica Integral Internacional de Oncología S de RL de CV Heroica Puebla de Zaragoza Puebla
Mexico The American British Cowdray Hospital/ Hospital Abc; Oncology Mexico City
Philippines Cebu Doctors' University Hospital; Research Office Cebu City
Philippines St Lukes Medical Center Quezon City
Poland Instytut Genetyki i Immunologii GENIM Lublin
Poland Narodowy Instytut Onkologii im. M. Sklodowskiej-Curie; Oddzial Badan Wczesnych Faz Warszawa
Portugal Hospital da Luz; Departamento de Oncologia Medica Lisboa
Portugal Hospital CUF Porto; Servico Pneumologia Porto
Portugal IPO do Porto; Servico de Oncologia Medica Porto
Saudi Arabia National Guard King Abdulaziz Medical City; Oncology Riyadh
Serbia Oncomed-System Belgrade
Serbia SIRIUS Medical Belgrade
Serbia Special hospital for internal diseases Vesalius Belgrade
Serbia University Hospital Medical Center Bezanijska kosa Belgrade
Serbia Oncology Institute of Vojvodina Sremska Kamenica
Slovakia Narodny Onkologicky Ustav; Oddelenie klinickej onkologie A Bratislava
Slovenia University Clinic Golnik Golnik
Slovenia Institute of Oncology Ljubljana Ljubljana
South Africa Medical Oncology Centre of Rosebank; Oncology Johannesburg
South Africa Wilgers Oncology Centre Pretoria
Spain Complejo Hospitalario de Jaen-Hospital Universitario Medico Quirurgico; Servicio de Oncologia Jaen
Spain Fundacion Jimenez Diaz; Servicio de Oncologia Madrid
Spain HM Sanchinarro ? CIOCC; Servicio de Oncologia Madrid
Spain Hospital Universitario Son Espases; Servicio de Oncologia Palma De Mallorca Islas Baleares
Spain Clinica Universitaria de Navarra; Servicio de Oncologia Pamplona Navarra
Spain Hospital Universitario Miguel Servet; Servicio Oncologia Zaragoza
Taiwan Chang Gung Medical Foundation - Kaohsiung; Oncology Kaohisung
Taiwan Taipei Veterans General Hospital Taipei City
Taiwan Chung Gung Memorial Hospital; Oncology Taoyuan County
Thailand Chulalongkorn Hospital; Medical Oncology Bangkok
Thailand Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. Oncology Bangkok
Turkey Memorial Ankara Hastanesi Ankara
Turkey Trakya University Medical Faculty Edirne
Turkey Ba?c?lar Medipol Mega Üniversite Hastanesi; Oncology Istanbul
Turkey Medicana International Atasehir Hospital Istanbul
Turkey Ac?badem Maslak Hastanesi Büyükdere Sar?yer/?stanbul
Turkey Ac?badem Adana Hospital, Oncology Department Seyhan/Adana
United Arab Emirates Mediclinic City Hospital Dubai
United Kingdom Bristol Haematology and Oncology centre Bristol
United Kingdom Royal Sussex County Hospital; Clinical Research Facility Eastbourne
United Kingdom Royal Devon & Exeter Hospital; Oncology Centre Exeter
United Kingdom St Georges University Hospitals NHS Foundation Trust London
United Kingdom Christie Hospital Nhs Trust; Medical Oncology Manchester
United Kingdom Freeman Hospital; Northern Centre For Cancer Care New Castle Upon Tyne
United Kingdom Torbay Hospital; Oncology Torquay
Vietnam Hanoi Oncology Hospital Hanoi
Vietnam K hospital Hanoi
Vietnam Ho Chi Minh City Oncology Hospital Ho Chi Minh City

Sponsors (1)

Lead Sponsor Collaborator
Hoffmann-La Roche

Countries where clinical trial is conducted

Argentina,  Austria,  Brazil,  Canada,  Chile,  Colombia,  Egypt,  Estonia,  France,  Germany,  Greece,  India,  Ireland,  Israel,  Lebanon,  Mexico,  Philippines,  Poland,  Portugal,  Saudi Arabia,  Serbia,  Slovakia,  Slovenia,  South Africa,  Spain,  Taiwan,  Thailand,  Turkey,  United Arab Emirates,  United Kingdom,  Vietnam, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall Survival From date of registry entry until death, for up to 5 years
See also
  Status Clinical Trial Phase
Completed NCT03315091 - Phase I Study to Assess the Effect of Food on AZD1775 Pharmacokinetics in Patients With Advanced Solid Tumours Phase 1
Completed NCT01921140 - To Determine the Effect of Food on the Pharmacokinetics of Olaparib and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours Phase 1
Completed NCT00732420 - Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors Phase 1
Recruiting NCT03572192 - Tissue Collection Framework To Improve Outcomes In Solid Tumours
Completed NCT02360345 - Phase I Trial of ONX-0801 Once Weekly or Alternate Weekly Phase 1
Completed NCT02264418 - Safety and Tolerability of ODM-203 in Subjects With Advanced Solid Tumours Phase 1
Completed NCT02093351 - To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer Phase 1
Completed NCT01956669 - Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors Phase 2
Recruiting NCT02215850 - Safety Study of SLC-0111 in Subjects With Advanced Solid Tumours Phase 1
Recruiting NCT02263950 - A Phase 1/2a Study of LON002 in Subjects With Advanced Solid Tumours Phase 1/Phase 2
Completed NCT01931761 - Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C] Selumetinib in Volunteers Phase 1
Completed NCT01900028 - To Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of Olaparib, and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation to Patients With Advanced Solid Tumours Phase 1
Completed NCT00136578 - Ispinesib In Combination With Carboplatin In Patients With Solid Tumors Phase 1
Completed NCT01184274 - A Phase I Study of SB939 in Pediatric Patients With Refractory Solid Tumours and Leukemia Phase 1
Withdrawn NCT03266159 - A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity of GSK525762 Plus Trametinib in Subjects With Solid Tumors Phase 2
Active, not recruiting NCT01894256 - Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal or Impaired Kidney Function Phase 1
Completed NCT01974349 - To Assess the Effect of Food on the Pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers Phase 1
Completed NCT02923947 - Study to Assess Osimertinib in Patients w/ Adv Solid Tumours & Normal Kidney Function or Severe Kidney Impairment Phase 1
Completed NCT02063204 - To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Renal Impaired Subjects and Healthy Subjects Phase 1
Completed NCT02056392 - To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers Phase 1

External Links